Jennifer Treusch, MD
Psychiatry · Tucson, AZNPI 1992075675
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,401 of the $29,124 with a category attached, or 63.2%. 23 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 52.9% of the total. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 568 payments — averaging $51.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$15K
- AbbVie$8K
- Takeda Pharmaceuticals U.S.A., Inc.$801
- Neurocrine Biosciences, Inc.$674
- Almatica Pharma LLC$650
- Johnson & Johnson$632
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$18,40163%
- Travel & lodging$1,4145%
- Food & beverage$9,18232%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 68 | $15,402 |
| AbbVie(2 entities) | 188 | $7,694 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $801 |
| Neurocrine Biosciences, Inc. | 28 | $674 |
| Almatica Pharma LLC | 33 | $650 |
| Johnson & Johnson | 26 | $632 |
| Teva Pharmaceuticals USA, Inc. | 31 | $629 |
| Alkermes, Inc. | 25 | $525 |
| Lundbeck LLC | 28 | $486 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $442 |
| Vanda Pharmaceuticals Inc. | 14 | $300 |
| Sunovion Pharmaceuticals Inc. | 8 | $276 |
| Corium, LLC | 8 | $147 |
| Axsome Therapeutics, Inc. | 8 | $142 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $89 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Shire North American Group Inc | 3 | $41 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Biogen | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,124 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 125 | $187,848 |
| TrintellixVortioxetine Hydrobromide | 32 | $25,404 |
| VraylarCariprazine Hcl | 11 | $23,924 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $16,746 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 308 | $12,288 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $6,570 |
| Aripiprazole | 84 | $6,208 |
| Vilazodone Hcl | 83 | $5,812 |
| Lurasidone Hcl | 33 | $5,278 |
| Bupropion XlBupropion Hcl | 222 | $4,563 |
| Duloxetine Hcl | 152 | $3,287 |
| Buspirone Hcl | 213 | $3,139 |
| Atomoxetine Hcl | 21 | $3,069 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 99 | $2,510 |
| Lamotrigine | 161 | $1,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $632 | $187,848125 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $801 | $31,97444 claims |
| AbbVieVraylar | $7,694 | $23,92411 claims |
| Axsome Therapeutics, Inc.Auvelity | $142 | $16,74614 claims |
| Almatica Pharma LLCSertraline Hcl | $650 | $31283 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Tucson
- Marlene FreemanTucson$59K
- Francisco MorenoTucson$40K
- Samantha FrembgenTucson$9K
- Peter KowalskiTucson$8K
- Stephen StreitfeldTucson$6K
- Richard BarnesTucson$5K
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Bahar GolestanMesa$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.